Our goal is to move healthcare professionals to treat beyond HbA1C, prevent early cardiovascular and renal complications and explore non-alcoholic steatohepatitis (NASH)

Type-2 diabetes (T2D) is a medical condition in which the body cannot keep blood glucose levels normal, also known as insulin resistance. Globally, an estimated 425 million people are living with diabetes,1 and diabetes is predicted to become the seventh most common cause of death by 2030.2

People with type-2 diabetes have an increased risk of developing several serious life-threatening health problems, lowering quality of life for patients and increasing medical care costs.3-5

Addressing diabetes and other CVRM diseases

We are investigating the drivers of disease progression and link between cardiovascular, renal and metabolic disease areas (CVRM) to explore the use of our medicines in combination that might offer unique benefits for patients. Diabetes and our efforts to positively impact patients living with this disease is summarised in this infographic.

The progress being made to transform the diabetes treatment paradigm is truly inspiring. We continue to make significant strides in treating the whole patient and push the boundaries of science in advancing this vital research.


The patient experience

What a diabetes diagnosis means for patients

Being diagnosed with diabetes can come as a shock and patients might first feel overwhelmed or deny the disease.14 Type-2 diabetes is often stigmatised and perceived as the result of poor lifestyle choices.15,16 However, with the right support, patients can learn to cope with the disease and their emotions, finding a way to manage their disease, make lifestyle changes and adapt to their new way of life.17

425 million adults 

today suffer from diabetes. This is estimated to rise to 629 million by 2045.1

>93% of people

with type-2 diabetes have at least one other cardiovascular, renal or metabolic disease.3

6-12x higher risk

of developing end-stage renal disease in patients with type-1 diabetes.19

$1.3 trillion in 2015 to $2.5 trillion by 2030

The global economic burden of diabetes is projected to almost double.20

Our commitment

Today, we are focusing on developing our established treatments and medicines to help reach even more patients affected by metabolic diseases. By doing so, we hope to transform and evolve modern treatment guidelines. The call for innovation is clear for patients at unmet need and a health system in crisis. This is why we have developed industry-leading clinical programmes as well as mechanistic and extensive real-world evidence studies enabling us to identify and address those patient needs. By conducting health economics and outcomes research (HEOR), we are striving for pioneering solutions of patient care that benefit healthcare systems. Patients are at the centre of our efforts, and we want to achieve earlier response, avoiding serious outcomes for them.


Our people

The need for innovation to optimise treatment is clear for patients living with diabetes and a health system in crisis. We constantly encourage our people to challenge the limits of science to bring us closer to our ambition: help HCPs treat beyond HbA1C, prevent early cardio-renal complications and explore deeper into the mechanisms and complications of NASH.

Elisabeth Björk SVP, Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D

Discover more about CVRM


  1. Ogurtsova K, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.
  2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
  3. Arnold SV, et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab. 2018;20(8):2000–3.
  4. Einarson TR, et al. Economic burden of cardiovascular disease in Type 2 Diabetes: A systematic review. Value Health. 2018;21(7):881-90.
  5. Trikkalinou A, et al. Type 2 diabetes and quality of life. World J Diabetes. 2017;8(4):120–9.
  6. Raimundo M, Lopes JA. Metabolic syndrome, chronic kidney disease, and cardiovascular disease: A dynamic and life-threatening triad. Cardiol Res Pract. 2011;2011:747861. doi: 10.4061/2011/747861
  7. Martín-Timón I, et al. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5(4):444–70.
  8. Goderis G, et al. Long-term evolution of renal function in patients with type 2 diabetes mellitus: A registry-based retrospective cohort study. BMJ Open. 2013;3(12):e004029.
  9. Lee SJ, et al. Metabolic syndrome status over 2 years predicts incident chronic kidney disease in mid-life adults: A 10-year prospective cohort study. Sci Rep. 2018;8(1):12237.
  10. Chronic Kidney Disease. World Kidney Day. Available from URL:
  11. Tune JD, et al. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017;183:57–70.
  12. Wen CP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017;92(2):388–96.
  13. Ofstad AP, et al. The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. Heart Fail Rev. 2018;23(3):303–23.
  14. Diabetes UK. Diabetes and your emotions [cited 2019 Jul 1]. Available from URL:
  15. Browne JL, et al. ‘I call it the blame and shame disease’: A qualitative study about perceptions of social stigma surrounding type 2 diabetes. BMJ Open. 2013;3(11):e003384.
  16. Liu NF, et al. Stigma in people with type 1 or type 2 diabetes. Clin Diabetes. 2017;35(1):22-34.
  17. Diabetes UK. Just diagnosed with diabetes: how to cope [cited 2019 Jul 1]. Available from URL:
  18. American Heart Association. Know Diabetes by Heart: KNOW THE LINK; 2018 [cited 2019 Jul 1]. Available from URL:
  19. Koye DN, et al. The Global Epidemiology of Diabetes and Kidney Disease. Adv Chronic Kidney Dis. 2018;25(2):121-132.
  20. Bommer C, et al. Global economic burden of diabetes in adults: Projections from 2015 to 2030. Diabetes Care. 2018;41(5):963–70.